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Background: Doxycyline (Dox) is a semisynthetic antibacterial drug with pharmacological advantages over its
parent drug (tetracycline) in the treatment of various bacterial diseases in horses. Yet, at present a horse-customized
pharmaceutical formulation is not available. Based on its pharmacokinetic/pharmacodynamic (PK/PD) ratio, Dox is
considered a time-dependent antibacterial drug and ideally expected to achieve sustained plasma drug
concentrations both at or slightly above the minimal inhibitory concentration (MIC) level for as long as possible
between dosing intervals. Hence, the objective of this study was to formulate two long-acting (LA) doxycyline
hyclate (Dox-h) formulations for oral administration and define their pharmacokinetics in non-fasted adult horses to
obtain better bioavailability and longer mean residence time, features needed to comply better with its
pharmacokinetic/pharmacodynamic (PK/PD) ratios.
Results: Pharmacokinetic parameters were determined after the oral administration of a single 10 mg/kg bolus dose
of two 20% Dox-h formulations: one based on a β cyclodextrin (Dox-β) matrix and a second one on a poloxamer
(Dox-pol) matrix. The results were compared with the pharmacokinetics of a single 10 mg/kg bolus oral dose of a
freshly made aqueous Dox-h solution (Dox-a). Dox-pol showed the greatest values for relative bioavailability (548%);
maximum serum concentration (Cmax) value was 1.3 ± 0.7 μg/mL with time to reach the Cmax (Tmax) of 5.9 ± 1.7 h,
area under the curve (AUC) of 17.0 ± 2.2 μg h/ml and elimination half-life (T½ β) of 4.9 ± 1.0 h.
Conclusions: Considering a minimal inhibitory concentration MIC of 0.25 μg/mL, clinically effective plasma
concentrations might be obtained for up to 24 h administering Dox-pol. This is an oral paste formulation that might
optimize the use of Dox-h in horses in terms of PK/PD ratio congruency, and it is likely that it may also improve
prescription compliance due to its ease of administration.
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Doxycycline hyclate (Dox-h), a semi-synthetic analog of
tetracycline, offers several pharmacological advantages over
the parent drug (tetracycline) in horses, mainly higher oral
bioavailability, higher tissue penetration, a larger volume of
distribution and exhibits a more potent antimicrobial activ-
ity [1-5]. Additionally, Dox-h is better tolerated than other
tetracyclines in this species; hence, the risk of enterocolitis
and diarrhea is milder and/or infrequent [6,7].* Correspondence: sumano@unam.mx
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reproduction in any medium, provided the orThe intramuscular and subcutaneous administration of
Dox-h can cause extreme local pain, irritation and tissue
necrosis and these routes are therefore not recommended
[7,8]. The intravenous use should also be avoided, as it can
cause supraventricular tachycardia, systemic arterial hy-
pertension, clinical signs of discomfort, cardiovascular col-
lapse and even death in horses [9,10].
The pharmacokinetics of an aqueous solution of Dox-h
administered orally (PO) has been determined in adult
horses [1,6,11,12] and in foals [2]. In these studies, Dox-h
was administered either dissolved in water via nasogastric
tube or as a top dressing at doses ranging from 3 mg/kg to
20 mg/kg every 12 (q12h) or every 24 hours (q24h). Davis
et al. [6] determined that after administering single orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the time to maximum concentration (Tmax) was 1.6 ±
1.3 x`h, the maximum concentration (Cmax) was 1.7 ± 0.3
μg/mL and elimination half-life (T½β) was 12.07 ± 3.1 h.
Plasma protein binding was 81.7 ± 2.4%. These authors
concluded that Dox-h administered at a dosage of 20 mg/
kg PO q24h will result in drug concentrations adequate
for inhibiting intracellular bacteria and bacteria with min-
imal inhibitory concentration (MIC) equal or higher than
0.25 μg/mL. On the other hand, Bryant et al. [1] con-
cluded that Dox-h at a dose of 10 mg/kg PO q12 h could
be appropriate for treating infections caused by susceptible
(MIC < 0.25 μg/ml) gram positive microorganisms. Yet,
Davis et al. [6] and Womble et al. [2] consider that the
therapeutic value of oral Dox-h in adult horses is limited
due to its low bioavailability. Winther et al. [12] reported
an estimated oral bioavailability of Dox-h of 17% after
intragastric administration and 6% after topdressing ad-
ministration in non-fasted adult horses. Similarly, these
authors consider that if the oral bioavailability of Dox-h
could be enhanced, this antimicrobial drug might be a
valuable resource for the treatment of lower airway infec-
tions in horses. Additionally, a high local drug concentra-
tion of Dox-h in the stomach causes gastric irritation and
nausea in humans [13,14] and it has been shown that
retarding the release of Dox-h diminishes the incidence of
gastrointestinal adverse side effects [15].
Considering the above, the objective of the present
study was to formulate and define the pharmacokinetics
of two long-acting (LA) Dox-h formulations intended
for oral administration in horses, with the aim of im-
proving its bioavailability and its gastrointestinal toler-
ance in an attempt to enhance the value of Dox-h as an
antimicrobial drug in equine medicine.
Methods
The study was conducted in Mexico City campus of the
School of Veterinary Medicine at the National Autono-
mous University of Mexico (UNAM). The study was ap-
proved by the Postgraduate Committee of Research,
Care, and Use of Experimental Animals in accordance
with its regulations [16].
Ten healthy adult Quarter Horses (three mares and
seven geldings) weighing a mean of 450 ± 22.4 kg were in-
cluded in the study. The animals were considered clinic-
ally healthy on the basis of physical examination and
standard hematological and biochemical tests. The horses
had not been medicated with any antimicrobial agent for
at least 30 days before enrollment in the study. They were
maintained on a diet of oat hay and feed concentrate and
had ad libitum access to water throughout the study.
Three preparations were assessed; two experimental
LA formulations and an aqueous one. The first LA for-
mulation was the Dox-h in a poloxamer base (Dox-pol;200 mg/mL), prepared as follows: first Dox-h powder
(PARFARM S.A., Mexico) was made soluble in distilled
water. Then, a reverse gel copolymer polyoxypropile–
polyoxyethylene poloxamer 407 (Lutrol micro 127 MP
(BASF Germany) was added and stirred vigorously and
constantly at 4°C. The mixture was protected from sunlight
and maintained at 2 – 4°C during 24 h. It was then further
homogenized to obtain a clear solution. Carbomer 934P
(Carbopol 934P, Lubrizol USA) was added to increase vis-
cosity. After stirring continuously during 30 minutes, it
was considered ready when a microemulsion was formed.
This point could be determined when the mixture clarified.
Xanthan gum (Padoquimia S.A., Mexico) was then added
to obtain a suspension with a paste-like consistency ready
to use. Finally, 35 mL syringes were filled up with the 20%
Dox-pol formulation, protected from light and the formu-
lation used within three days after preparation.
The Dox-h–β cyclodextrin (Dox-β) on a poloxamer
base formulation was prepared, by first forming com-
plexes of Dox-h 20% (w/v) with β-cyclodextrin (Cerestar
Pharmaceutical Excipients, U.S.A.). For this purpose the
kneading method was used [17]. The ingredients were
first mixed in a mortar to obtain a homogeneous paste.
Then, Dox was added slowly. The mixture was further
grounded for 30 min and an appropriate quantity of
water was added to maintain a paste-like consistency. It
was then dried in an oven at 40-50°C for 24 h. The dried
complex was pulverized into a fine powder, which was
then diluted in water. This mixture was then included in
a reverse gel copolymer polyoxypropile–polyoxyethylene
poloxamer 407 (Lutrol micro 127 MP (BASF Germany)
under constant stirring at 4°C. The preparation was
regarded as ready when a micro-emulsion is formed and
this could be pin-pointed when the mixture clarified. Xan-
than gum (Padoquimia S.A., Mexico) was then added to
obtain a suspension with a paste-like consistency ready to
use. Finally, 35 mL syringes were filled up with the 20%
Dox-β formulation, protected from light and the formula-
tion used within three days after preparation. This experi-
ment does not intend to present stability studies for this
preparation, and has no proprietary restrictions.
Finally, an aqueous formulation of Dox-h (Dox-a) was
prepared from powdered Dox-h by diluting it in sterile
distilled water, obtaining a 20% final solution and imme-
diately administered to the horses.
Individual dose vs. pharmaceutical preparation compli-
ance was calculated to have 5.5, 4.2 and 2.8% error from
the set dose of 10 mg/kg in the Dox-β, Dox-pol and Dox-a
(1 mL/20 kg of body weight in all cases), as assessed by
determining Dox-h concentration in all three prepara-
tions, taking 4 random test samples of each group. Deter-
mination of Dox-h in by HPLC with UV detection in
these pharmaceutical samples was carried out as described
by Axisa et al. [18].
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employed with washout periods of 21 days. Each horse
was individually weighed and dosed with the Dox-a
preparation via nasogastric tube at a dose of 10 mg/kg
in a volume of approximately 30 mL. After the washout
period, each horse of the same experimental group was
moved to the next group and dosed at 10 mg/kg with ei-
ther Dox-β (30 mL approximately), or Dox-pol, also at
10 mg/kg in a volume of 30 mL approximately. These
latter groups received their dose as a paste, placed in the
interdental space aided by a long tipped syringe. In all
three groups adverse gastrointestinal drug reactions i.e.,
colic, diarrhea and other signs of abdominal discomfort
were sought for hourly during the day.
Determination of pharmacokinetic values was accom-
plished through serial blood sampling.
To achieve accurate intervals between administration
of the drug and collection of serum, a 16-gauge, per-
manently heparinized catheter was inserted into a jugu-
lar vein and glue-fixed on each horse. Blood samples
were obtained before administration of any of the for-
mulations (time 0), and after the administration of each
of the preparations, at 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 24
and 48 h. Blood samples were obtained by removing 5
mL of heparin-containing blood from the catheter,
discarding it, and then collecting additional 5 mL of
blood, which were placed into 10 mL test tubes with no
anticoagulant. Blood was allowed to clot at room
temperature (20°C) during 30 minutes and then
centrifuged at 1500 RPM for 15 minutes. Serum was
harvested, frozen in liquid nitrogen and stored not more
than 7 days until analyzed.
Serum Dox concentrations were determined both by
high performance liquid chromatography (HPLC) as de-
scribed by Axisa et al. [18] and through the modified
agar diffusion analysis, described by Abd El-Aty et al.
[19]. For the former analytical analysis, the intra-assay
coefficient of variance was < 1.9 and interassay error was
< 1.8. The analytic assay was linear over a range of con-
centrations from 0.1 to 10 μg/mL. Mean ± 1 SD recovery
was 94 ± 2% (r = 0.97). Limit of detection was 0.07 μg/
mL, and limit of quantification was 0.1 μg/mL.
For the modified agar diffusion analysis, Bacillus ce-
reus (ATCC-11778) was used as a test organism grown
on Mueller-Hinton agar (MCD LAB, S.A. de C.V.,
Mexico City). The intra-assay coefficient of variance was
< 4.8 and inter-assay error < 4.6. The analytical assay was
linear over a range of concentrations from 0.04 to 10
μg/mL, with a percent recovery of 93 ± 2 and a correl-
ation coefficient (r) of 0.97 ± 0.1. Limit of detection was
0.005 μg/mL and limit of quantification was 0.01 μg/mL.
Compliance between both methods to determine se-
rum concentrations of Dox-h was carried out using
doxycycline-spiked horse serum samples and processedby the two analytical techniques. Subtraction of recover
percentages revealed an error of no more than 6.2%.
A computerized curve stripping program (PK Analyst
for Windows, MicroMath, St. Louis, MO) was used to fit
and analyze the concentration-versus-time profiles for each
horse and the mean values for each group. Models of best
fit (r ≥ 0.99) were chosen after analysis by use of residual
sum of squares and the minimal Akaike’s information cri-
terion. The best fit for Dox-a was obtained by using a 2
compartment model with first-order input and first order
output in accordance with the following equation:
Concentration Timeð Þ ¼ Aea Time þ Beβ Time
þ CeKAB Time
Pharmacokinetic variables obtained for Dox- a were:
elimination rate constant (Kel), absorption rate constant
(Kab), area under the curve (AUC), half life of the elimin-
ation phase (T ½ β), absorption half life (T½ ab), mean
residence time (MRT), mean residence time to infinity
(MRT 0 - ∞), area under the curve to infinity (AUC0 - ∞)
and area under the moment curve to infinity (AUMC0 - ∞).
The best fit for Dox-pol and Dox-β was obtained by
using a one-compartment model with first-order input
and first order output in accordance with the following
equation:
Concentration Timeð Þ ¼ Dose KAB
Volume KAB  Kelim
eKel Time–eKAB Time
The pharmacokinetic values obtained for Dox-pol and
Dox-β were: elimination rate constant (Kel), absorption
rate constant (KAB), area under the curve (AUC), area
under the first moment of the concentration-time curve
(AUMC), half life of the elimination phase (T½β), ab-
sorption half life (T½ab), time when the concentration
reaches its maximum (Tmax), the maximum concentra-
tion (Cmax), mean residence time (MRT), mean resi-
dence time to infinity (MRT 0 - ∞), area under the curve
to the last time point (AUC 0 - ∞ ) and area under the
moment curve to infinity (AUMC0 - ∞ ). Table 1 summa-
rizes the pharmacokinetic variables obtained. Data
showed no normal distribution for all three groups and
are presented as mean ± standard deviation of 10 obser-
vations for each parameter. Statistical comparison was
made by Kruskal-Wallis and Dunn test.
Relative bioavailability was calculated comparing the
long acting formulations with the Dox- a preparation, by
using the following equation as described by Sabnis [20]:
Relative bioavailability Frelð Þ ¼ AUCDox pol=AUCDox að Þ
 100
The degree of plasma protein binding of Dox was car-
ried out in vitro as described by Singhvi et al. [21]. Dox-
enriched plasma samples were spiked with 0.1, 0.5, 1, 5,
Table 1 Pharmacokinetic variables for doxycycline hyclate
(Dox-h) in horses after the oral administration of three
experimental formulations
Dox-a Dox-pol| Dox-β
Mean ± SD Mean ± SD Mean ± SD
AUC (μg · h/mL) 3.1 ± 0.2 a 17.0 ± 2.2b 1.5 ± 0.1 c
AUMC (μg · h2/mL) 35.2 ± 1.2 a 208.3 ± 31.1b 12.3 ± 0.1 c
AUC0 - ∞ (μg · h/mL) 3.0 ± 0.2 a 16.1 ± 4.8 b 1.5 ± 0.9 c
AUMC0 - ∞ (μg · h2/mL) 31.2 ± 2.3 a 171.3 ± 5.8 b 12.3 ± 0.5 c
MRT (h) 11.3 ± 4.4 a 12.2 ± 4.2a 8.1 ± 2.1 a
MRT0 - ∞ (h) 10.2 ± 2.6
a 10.7 ± 2.1 a 8.1 ± 1.2 a
T½β (h) 2.8 ± 0.9a 4.9 ± 1.0b 4.2 ± 0.9b
T½ab(h) 1.2 ± 0.2
a 3.5 ±1.2 b 1.4 ± 0.1 a
Kel (h
-1) 0.2 ± 0.0 a 0.1 ± 0.1 a 0.2 ± 0.1 a
Kab (h-1) 1.6 ± 0.2 a 0.2 ± 0.2 b 0.5 ± 0.3 c
α (h-1) 1.2 ± 0.0 - -
β (h-1) 9.2 ± 0.0 - -
Cmax (μg/mL) 0.3 ± 0.1 a 1.3 ± 0.7 b 0.2 ± 0.0 c
Tmax (h) 2.2 ± 0.4 a 5.9 ± 1.7 b 3.4 ± 0.6 c
Frel (%)* - 548% a 48% b
a,b,c, The values within a row with no common superscript differ significantly
(P < 0.05).
* Mean of means.
AUC, Area under the concentration-time curve; AUC 0 - ∞, Area under the
concentration –time to infinity; AUMC, Area under the first moment of the
concentration-time curve; AUMC 0 - ∞, Area under the first moment of the
concentration-time curve to infinity; MRT, Mean residence time; MRT 0 - ∞,
Mean residence time to infinity; α, distribution hybrid rate constant; β,
elimination hybrid rate constant; A, B,, zero time intercepts of the distribution
and post-distribution phases; Kel, Elimination rate constant from the central
compartment; Kab, Absorption rate constant; T½ab, Absorption half-life; T½β,
Elimination half-life; Cmax, Calculated maximum plasma concentration; Tmax,
Time of maximum plasma concentration; Frel, Relative bioavailability.






















Figure 1 Concentration vs time profile of doxycycline (Dox) in
serum after administration of three experimental oral
formulations in horses.
F1
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mercial ultrafiltration Waters Oasis solid-phase extrac-
tion cartridges (Waters Associates, Milford, MA). The
ultrafiltrate was centrifuged at 1,200 × g for 30 min at
37°C to further separate plasma proteins. This resulted
in an ultrafiltrate volume of at least 200 μL that was fro-
zen until assayed. The resulting filtrates were used to
compare the degree of Dox protein binding as compared
with unprocessed samples, using the same microbio-
logical analysis. The percentage of protein-bound frac-
tion (B) was calculated according to the following
equation: B = (initial plasma concentration − ultrafiltrate
concentration)/initial plasma concentration × 100. The
CV for this method were <4.2%.
Results
Figure 1 shows the mean ± 1 SD of the serum concentra-
tions of Dox vs time for the three drug preparations
(Dox-β, Dox-pol and Dox-a). Table 1 summarizes the
pharmacokinetic variables obtained and statistical differ-
ences are highlighted.Maximum serum concentration (Cmax ) was highest in
the Dox-pol group (1.3 ± 0.7 μg/mL) at a Tmax of 5.9 ±
1.7 h. Elimination half-life (T½β) in the Dox-pol group
was 4.9 ± 1.0 h, a similar value was obtained for Dox-β
(4.2 ± 0.9 h), while T½β determined after the administra-
tion of Dox-a was 2.8 ± 0.9 h. Dox-β had considerably
lower plasma concentrations throughout the established
sampling period as compared to the other two groups.
The AUC for plasma concentrations was higher for Dox-
pol (17 ± 2.2 μg h/ml), intermediate for Dox-a (3.1 ± 0.2
μg h/ml) and lowest for Dox- β (1.5 ± 0.1) (P < 0.01).
Plasma protein binding did not differ among groups and
was consistently 80.3 ± 1.5%.
Relative bioavailability of the two long-acting prepara-
tions as compared to Dox-a was 548% for Dox-pol and
48% for Dox-β (P < 0.01).
Discussion
Agreement between the quantitative/qualitative microbio-
logical agar diffusion technique and the high performance
liquid chromatography method used in this trial to deter-
mine serum concentrations of Dox, can be regarded as suf-
ficiently reliable to assume that concentrations obtained
through HPLC are biologically active. That is, because the
microbiological agar diffusion test determines the active
fraction(s) of the drug, it offers clinically meaningful data,
and in this case such assumption has been validated
through a purely chemical method. This allows straightfor-
ward speculations on the relationships between serum con-
centrations and dosing intervals for specific pathogens.
Serum concentrations obtained after the administration
of Dox-β were noticeably low (Cmax = 0.2 ± 0.0 mg/mL;
AUC = 1.5 ± 0.1 μg · h/mL). These values are not within
the range that would be effective for many equine patho-
gens [1,22], and are only considered marginally for further
analysis in this section.
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h administered orally has been determined in adult
horses [1,6,11,12] at a dose range from 3 to 20 mg/kg.
Davis et al. [6] obtained a Cmax of 0.9 ± 0.2 μg/mL with
a Tmax of 1.6 ± 1.3 h, administering a single dose of 20
mg/kg PO. By comparison Cmax obtained with Dox-a in
this study, at a single 10 mg/kg dose was 0.3 ± 0.1 mg/mL
with a Tmax of 2.2 ± 0.4 h. Differences between these two
studies can be safely related to the dose and biological
variability, but it relates mainly to the fact that the former
study used fasted horses. In contrast, Cmax and Tmax
values for Dox-pol were 1.3 ± 0.6 μg/mL and 5.9 ± 1.6 h,
respectively, also at a dose of 10 mg/kg. By comparison
higher Cmax at a lower or the same dose may be the result
of a concentration build-up due to a zero order absorption
kinetics caused by the polymers in the preparation along a
greater absorption surface area of the GI tract. This would
also explain the longer Tmax observed. The AUC obtained
administering 20 mg/kg as reported by Davis et al. [6] was
13.3 ± 2.7 μg.h/mL, while the AUC obtained with the Dox-
pol formulation at half their dose was 17.0 ± 2.2 μg.h/mL.
This finding is not unusual for LA preparations that ex-
hibit flip-flop kinetics [23] and may also explain the
relative bioavailability which reaches an unusual 548%.
In turn, to demonstrate flip-flop pharmacokinetics, the
overall appearance of the serum concentration vs. time
profile of the drug must be accounted for. Occasionally,
as in this case, the slower rate of absorption as com-
pared to the rate of elimination is not a straightforward
conclusion to be drawn. If a much longer apparent
elimination half-life following extravascular dosing is ob-
served compared with the IV route, it suggests that flip-
flop pharmacokinetics is occurring [24]. However this is
not possible with Dox considering that IV administra-
tion of this drug in horses is not recommended [9,10].
Thus, applying the following equation and based on
information taken from published work [25,26], a flip-
flop condition may be demonstrated with the follo-
wing equation:
Rate of Absorption ¼ Vz KC þ ΔC=Δtð Þð
Where Vz is the terminal exponential volume of distri-
bution, K is the terminal disposition rate constant once
drug absorption is complete, C is the plasma concentra-
tion at time t and ΔC is the change in plasma concentra-
tion over the time interval Δt. For Dox-pol plasma
concentration-time data at 4 and 12 h , ΔC/Δt = 0.0176
μg/mL/h. At the midpoint of this time period (8 h), (K)
(C) = 0.1339 μg/mL/hr. Since KC >ΔC/Δt, rate of ab-
sorption ≈ rate of elimination, a “flip-flop” condition ex-
ists and the Dox-pol formulation here described can be
regarded as a true long-acting one.As far as Dox-pol is concerned, poloxamer 407, a poly-
ethylene oxide-polypropylene oxide- polyethylene oxide
triblock co-polymer, was used as delivery vehicle-matrix.
It has been shown that it enhances solubility and perme-
ability, often resulting in improved oral bioavailability, as
reported by Kahn et al. [27] using atorvastatin, carba-
mazepine and other poorly soluble drugs. Considering
the permeability and solubility rates of doxycycline, there
is controversial information regarding the classification
of this drug in the Biopharmaceutics Classification Sys-
tem (BCS) for humans [28]. Initially Amidon et al., [29]
classify this drug in Class IV, that is, poorly soluble and
poorly permeable. More recently, however, Chavda et al.
[30] include Dox in Class I; that is, Dox is highly soluble
and highly permeable, which shows no coherence
when analyzing its reported absolute bioavailability in
horses i.e., from 2.8% to 17% [12,31]. In this study, ab-
solute bioavailability of Dox for the two long-action
formulations (Dox-pol and Dox-β) was not determined
because the IV kinetics of the drug is needed, and risk
of cardiovascular toxicity was avoided [10]. The Frel for
Dox-pol and Dox-β was 548% and 48%, respectively,
as compared to Dox-a, in non-fasted horses. Even though
decreased oral absorption of Dox has been demonstrated
in fed horses [31,32], it is here theorized that other fac-
tors could have enhanced bioavailability of Dox adminis-
tered in the Dox-pol formulation: mucoadhesiveness
achieved by poloxamer, carbopol and xanthan gum in the
formulation [33-35], perhaps enterohepatic circulation
considering that, with few exceptions, this phenomenon
is recognized as a common physiological peculiarity of
tetracyclines [36], and a greater amount of fluid partici-
pating to produce better Dox dissolution in the horses’
entire gastrointestinal lumen. This may allow absorption
along other surfaces of the GI tract [31]. Additionally,
total transit time from mouth to colon in adult horses is
of approximately 40 h [37], a fact that complies well with
the former reasoning. However, further studies are
warranted to define these phenomena.
The benefits of the controlled delivery of drugs in-
clude: the maintenance of serum drug concentration at
an optimal therapeutic level for a more prolonged time-
interval, reduction in handling and consequently, a pos-
sible improvement in drug-administration compliance
[38]. In this context, the Dox-pol preparation here de-
scribed was capable of providing with a single oral ad-
ministration, useful serum concentrations of this
antibacterial drug for 24 h, but not longer. Although it
has been stated that high concentrations of Dox in vitro,
equivalent to 8 to 16 times the value of an average MIC
could turn this time-dependent antibacterial drug into a
concentration-dependent antibacterial drug [39], its car-
diac toxicity refrains its use at higher doses. Hence, seek-
ing large Cmax values is an unsafe approach [40,41].
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rial drug in horses. In that context a better PK/PD ratio
can be achieved when serum concentrations of the drug
are barely above or at the MIC level of the involved
pathogen for as long as possible within the dosing inter-
val [36,42]. Values of MIC that can be adopted in this
trial can be set from 0.25 to 1.0 μg/mL [6,22] Hence, the
length of time in which minimum therapeutic concen-
trations can be achieved with Dox-pol varies from 12 to
24 h. Additionally, in humans, a PK/PD index accepted
as predictor of therapeutic efficacy for tetracyclines as a
group is the ratio of AUC0-24 (AUC0-24)/MIC [43]. If a
MIC of 0.25 μg/mL is considered, the AUCDOX-pol/MIC
ratio is 68.02 and the AUCDOX-a/MIC ratio is only 12.4.
Considering the above, it is safe to regard Dox-pol as a
drug preparation that possesses better PK/PD ratios to
control bacterial diseases in horse as compared to Dox-a.
Conclusions
Dox-pol is an oral paste formulation that optimizes the
use of doxycycline in horses in terms of PK/PD ratio con-
gruency, and it is likely that it may also improve prescrip-
tion compliance, due to its ease of administration. This
may contribute to diminish the emergence of bacterial re-
sistance. Nevertheless and although no adverse gastro-
intestinal reactions (diarrhea, colic, abdominal discomfort)
were observed in any of the horses used in this trial, mul-
tiple dose, tissue distribution and toxicological studies are
needed before clinical trials are set, to assess if this prepar-
ation can be regarded as potentially useful in this species.
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